ProShare Advisors LLC lifted its holdings in ICU Medical, Inc. (NASDAQ:ICUI - Free Report) by 45.9% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 6,613 shares of the medical instruments supplier's stock after acquiring an additional 2,081 shares during the period. ProShare Advisors LLC's holdings in ICU Medical were worth $1,026,000 at the end of the most recent quarter.
Several other institutional investors and hedge funds also recently added to or reduced their stakes in ICUI. Vanguard Group Inc. increased its position in ICU Medical by 0.7% during the fourth quarter. Vanguard Group Inc. now owns 2,682,065 shares of the medical instruments supplier's stock valued at $416,176,000 after acquiring an additional 17,805 shares during the last quarter. JPMorgan Chase & Co. boosted its stake in shares of ICU Medical by 7.4% during the 4th quarter. JPMorgan Chase & Co. now owns 708,382 shares of the medical instruments supplier's stock worth $109,920,000 after purchasing an additional 49,108 shares during the period. Dimensional Fund Advisors LP grew its holdings in ICU Medical by 18.2% during the 4th quarter. Dimensional Fund Advisors LP now owns 539,981 shares of the medical instruments supplier's stock valued at $83,788,000 after purchasing an additional 82,982 shares during the last quarter. Northern Trust Corp lifted its stake in ICU Medical by 11.1% in the fourth quarter. Northern Trust Corp now owns 402,342 shares of the medical instruments supplier's stock worth $62,431,000 after purchasing an additional 40,187 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. lifted its stake in ICU Medical by 1.0% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 304,155 shares of the medical instruments supplier's stock worth $47,196,000 after purchasing an additional 3,048 shares during the last quarter. Hedge funds and other institutional investors own 96.10% of the company's stock.
Insiders Place Their Bets
In other news, insider Ben Sousa sold 2,000 shares of ICU Medical stock in a transaction on Thursday, May 15th. The shares were sold at an average price of $137.36, for a total transaction of $274,720.00. Following the completion of the sale, the insider now directly owns 479 shares in the company, valued at approximately $65,795.44. The trade was a 80.68% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, COO Christian B. Voigtlander sold 5,555 shares of the company's stock in a transaction on Thursday, May 15th. The shares were sold at an average price of $135.55, for a total value of $752,980.25. Following the completion of the transaction, the chief operating officer now directly owns 2,389 shares in the company, valued at approximately $323,828.95. The trade was a 69.93% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 26,167 shares of company stock valued at $3,571,788. 1.50% of the stock is currently owned by corporate insiders.
ICU Medical Stock Down 1.0%
ICU Medical stock traded down $1.29 during midday trading on Wednesday, hitting $129.15. 28,445 shares of the company's stock were exchanged, compared to its average volume of 276,578. The company has a debt-to-equity ratio of 0.75, a quick ratio of 1.03 and a current ratio of 2.29. The company has a market cap of $3.18 billion, a PE ratio of -28.23 and a beta of 0.87. The firm has a 50-day moving average of $138.87 and a two-hundred day moving average of $151.88. ICU Medical, Inc. has a 12 month low of $100.91 and a 12 month high of $196.26.
ICU Medical (NASDAQ:ICUI - Get Free Report) last released its quarterly earnings results on Thursday, May 8th. The medical instruments supplier reported $1.72 EPS for the quarter, beating the consensus estimate of $1.23 by $0.49. ICU Medical had a negative net margin of 4.74% and a positive return on equity of 5.05%. The business had revenue of $599.49 million during the quarter, compared to analyst estimates of $574.15 million. During the same period in the prior year, the firm posted $0.96 earnings per share. The company's quarterly revenue was up 6.7% on a year-over-year basis. As a group, analysts expect that ICU Medical, Inc. will post 4.11 earnings per share for the current fiscal year.
Analyst Upgrades and Downgrades
ICUI has been the topic of several recent analyst reports. Raymond James reduced their price target on ICU Medical from $197.00 to $187.00 and set a "strong-buy" rating on the stock in a report on Friday, May 9th. KeyCorp reduced their target price on ICU Medical from $209.00 to $191.00 and set an "overweight" rating on the stock in a research note on Monday, April 21st. Needham & Company LLC reiterated a "hold" rating on shares of ICU Medical in a research report on Tuesday, April 8th. Finally, Wall Street Zen raised shares of ICU Medical from a "hold" rating to a "buy" rating in a research note on Sunday, May 18th. One investment analyst has rated the stock with a hold rating, three have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of "Buy" and a consensus target price of $192.67.
Get Our Latest Research Report on ICU Medical
ICU Medical Company Profile
(
Free Report)
ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.
Recommended Stories

Before you consider ICU Medical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ICU Medical wasn't on the list.
While ICU Medical currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report